Loading patent…
AssigneeThe Chemo-Sero-Therapeutic Research Institute
InventorsShinji NAKAHIRA, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
Estimating the term…
A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.
A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering A2 NTX to the patient.
A method for treating a patient suffering from a disease with muscle overactivity who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering A2 NTX to the patient.
Dependencies are inferred from the claim text.